次に

自動再生

Peptide Receptor Radionuclide Therapy (PRRT)

3 ビュー • 07/09/23
シェア
埋め込む
administrator
administrator
加入者
0

One of the most significant treatment options for neuroendocrine cancer patients became available with the 2018 FDA approval of Lutathera®, the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT).

NET experts Dr. Emily Bergsland, Dr. Pamela Kunz, Dr. Erik Mittra and Dr.
Jonathan Strosberg describe the treatment, how it works, and the benefits for patients.

What do physicians look forward to in the future for PRRT?

もっと見せる
0 コメント sort 並び替え
フェイスブックのコメント

次に

自動再生